HPV Self-Sampling: Cervical Screening You Can Do Yourself
HPV self-sampling lets you take your own vaginal swab for cervical screening. Here is how accurate it is, what the WHO says, where it is available in the UK and across Africa, and what happens after a positive result.
TL;DR: With HPV self-sampling you use a swab to collect your own vaginal sample, and a lab tests it for high-risk HPV. With the right lab test it finds pre-cancer about as well as a clinician-taken sample, and the WHO says either can be used. England began a phased rollout in August 2026, Scotland has started a first phase, and Wales has plans in place. Across Africa, it is mostly at the pilot or planning stage. A positive result is not a cancer diagnosis, but it does need a follow-up examination.
If the idea of a speculum has kept you away from cervical screening, or a past appointment was painful, frightening or humiliating, you are far from alone. Self-sampling was designed for exactly this. It means you can collect your own sample, in private, and only see a clinician if the test finds something that needs a closer look.
For the basics on the virus and the vaccine, see our guide to cervical cancer and HPV. Here we focus on the self-test, and on what is available right now. We checked the details in November 2026, and rollouts are moving quickly, so your local service may have changed since.
What is HPV self-sampling?
It is a cervical screening test where you take the sample yourself, usually with a soft swab placed in the vagina. The lab then checks it for high-risk HPV, the virus behind almost all cervical cancers. In England's programme, the kit comes with instructions, a video and a swab, and you send it back free in a prepaid envelope.
You do not need to reach your cervix. That is a common worry, and the swab is designed for a sample from the vagina.
How accurate is a self-test?
With a PCR-based lab test, it is very close to a clinician-taken sample. A large meta-analysis in the BMJ found PCR-based tests were as sensitive on self-samples as on clinician samples for finding serious pre-cancer (a ratio of 0.99). Tests based on an older method, signal amplification, were less sensitive on self-samples (0.85). Specificity, the ability to rule out disease, was slightly lower on self-samples, by about 2 percent with PCR tests.
So the kind of lab test matters. If you are paying privately, it is reasonable to ask whether the lab uses a PCR-based test, whether it has been validated for self-collected samples, and who will help you if the result is positive.
There is a fair difference in how experts describe this. The WHO says self-collected samples have been shown to be as reliable as those taken by health workers. Cancer Research UK says current evidence still favours a sample taken by a nurse or doctor, and describes self-testing as the next best option for people who would otherwise not be screened. On the practical point, the UK National Screening Committee judged self-sampling preferable to no test for people who do not currently attend.
What the WHO recommends
The WHO guideline prefers HPV DNA testing as the main screening method and suggests using either provider-taken or self-collected samples, for women in general and for women living with HIV. This is a conditional recommendation based on low-certainty evidence, which means the WHO thinks it is a sound option while acknowledging the evidence could be stronger.
The WHO also advises screening from age 30 every 5 to 10 years, and from age 25 every 3 to 5 years for women living with HIV.
Self-sampling also seems to bring more women into care. The same BMJ analysis found that posting kits to women's homes raised participation compared with invitation letters, although results varied widely between settings.
Can I get a self-test in the UK?
It depends on where you live and whether you are invited. As of November 2026:
England. The NHS began a gradual rollout on 25 August 2026. It starts with women aged 30 to 65 who have not attended screening after being invited. About four million invitations are planned in the first phase, sent through the NHS App, text, email or post, and it may not have reached your area yet. Invited women can order a free kit.
Scotland. A first phase launched in March 2026 in 22 GP practices across four health boards. It is for women over 30 who have never attended screening, or have not attended for at least six years, and aims to reach 17,000 women.
Wales. Targeted self-sampling through primary care was planned to begin in 2026, with a wider national rollout in late 2027.
Northern Ireland. We could not find a confirmed start date. The UK National Screening Committee has said all four UK countries should be allowed to offer self-sampling to people who never or rarely attend.
If you are not eligible yet, you can book a standard screening appointment at any time, even if your invitation came years ago. Our post on the UK cervical screening gap has ideas for making that appointment easier.
Self-sampling in Africa: what we could verify
Nigeria, Kenya, Ghana and South Africa are at different points, and self-sampling is not yet a routine national option in any of them, as far as we could confirm.
Kenya. The national cervical cancer elimination plan for 2026 to 2030, launched in January 2026, includes introducing self-sampling to increase screening uptake and expanding HPV testing to all 47 counties.
South Africa. A 2025 policy brief from the South African Medical Research Council calls for self-sampling to be added to the Essential Diagnostics List and National Health Insurance benefits, and for free kits through community health workers and mobile clinics.
Nigeria. In a randomised trial in a semi-urban area of Abuja, 93 percent of women offered self-collection submitted a sample, compared with 56 percent of those invited to a hospital. Public facilities in some states already use HPV testing and VIA, and it is worth asking your local clinic what they offer.
Ghana. Researchers report that no funded national HPV-based programme exists yet, so access to self-sampling is mainly through studies and private providers.
If you are offered a kit by a clinic, a campaign or a private provider, ask where the sample is tested, how you will get your result, and where you would go for follow-up. A test without a follow-up route leaves you with an answer and nowhere to take it.
What happens after a positive self-test?
You will need a further examination, because a self-test only checks for HPV. It cannot check your cervix for abnormal cells. In England, you are invited for a standard screening test with a nurse or doctor. A positive result does not mean you have cervical cancer.
Please do go to that appointment, even if you chose self-sampling to avoid one. A study of public clinics in three Nigerian states found that only 21 percent of women with a positive HPV result completed the examination they were referred for, and that is the gap that lets a preventable illness progress. Our post on what happens after an abnormal result takes you through the steps, including colposcopy and treatment. If the speculum is what worries you, tell the clinic in advance and ask what they can do to make it easier.
A negative result in England means no further tests, with your next invitation in 5 years if you are still in the eligible age range.
Who should see a clinician instead?
Screening is for people without symptoms. If you have unusual changes or symptoms, contact a doctor rather than waiting for a kit or an invitation. And if you have had the HPV vaccine, you should still be screened, since it does not protect against every high-risk type.
If you want to keep a note of when you were tested and what the result was, you can log it in Asele, and Amara can help you think through what to ask at your next appointment, in Yoruba, Hausa, Igbo, Swahili, French or English.
This post is education, not medical advice. Please speak to a qualified clinician about your own screening.
References
- Cancer Research UK. What does HPV self-testing mean for cervical screening in England? news.cancerresearchuk.org
- Arbyn M, et al. Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses. BMJ. 2018. pubmed.ncbi.nlm.nih.gov
- World Health Organization. Cervical cancer fact sheet. who.int
- World Health Organization. WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition. iris.who.int
- Nursing Times. Home-testing kits for cervical cancer risk rolled out in England. nursingtimes.net
- Scottish Government. Cervical cancer self-sampling programme launched. gov.scot
- Cancer Research UK. Cervical screening: research and optimisation. cancerresearchuk.org
- UK National Screening Committee. UK NSC recommends HPV self-sampling option for under-screened women. nationalscreening.blog.gov.uk
- WHO Regional Office for Africa. Kenya launches national cervical cancer elimination action plan 2026 to 2030. afro.who.int
- South African Medical Research Council. Integrating self-sampling: policy brief. 2025. samrc.ac.za
- Modibbo F, et al. Randomized trial evaluating self-sampling for HPV DNA based tests for cervical cancer screening in Nigeria. Infect Agent Cancer. 2017. pubmed.ncbi.nlm.nih.gov
- Lawson O, et al. Cervical cancer screening outcomes in public health facilities in three states in Nigeria. BMC Public Health. 2023. pubmed.ncbi.nlm.nih.gov
- Effah K, et al. A collaborative cervical precancer screening strategy across Ghana. PLoS One. 2026. pmc.ncbi.nlm.nih.gov
← Back to The Journal
